

Atty. Dkt. No. 065691-0387

IFW

**UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Christophe de ROMEUF  
Title: TREATMENT OF PATHOLOGIES WHICH  
ESCAPE THE IMMUNE RESPONSE, USING  
OPTIMIZED ANTIBODIES  
Appl. No.: 10/527,666  
International Filing Date: 9/15/2003  
371(c) Date: 8/1/2005  
Examiner: Crowder, Chun  
Art Unit: 1644  
Conf. No.: 7253

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of the non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

**RELEVANCE OF EACH DOCUMENT**


Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding International application. A copy of the International Search Report is attached setting forth the portion of each document considered relevant by the examiner. An English-language counterpart of the foreign-language document has been provided (A2 = A3).

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date August 9, 2006


By 

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5569  
Facsimile: (202) 672-5399

Stephen B. Maebius  
Attorney for Applicant  
Registration No. 35,264

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: August 9, 2006 <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/527,666</td> </tr> <tr> <td>Filing Date</td> <td>9/15/2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Christophe de ROMEUF</td> </tr> <tr> <td>Group Art Unit</td> <td>1644</td> </tr> <tr> <td>Examiner Name</td> <td>Crowder, Chun</td> </tr> <tr> <td>Attorney Docket Number</td> <td>065691-0387</td> </tr> </table>		Application Number	10/527,666	Filing Date	9/15/2003	First Named Inventor	Christophe de ROMEUF	Group Art Unit	1644	Examiner Name	Crowder, Chun	Attorney Docket Number	065691-0387
Application Number	10/527,666																
Filing Date	9/15/2003																
First Named Inventor	Christophe de ROMEUF																
Group Art Unit	1644																
Examiner Name	Crowder, Chun																
Attorney Docket Number	065691-0387																
Sheet	1	of	1														



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	6,180,377	B1	MORGAN et al.	01/30/2001	
	A2	2003-175969	A1	BELIARD et al.	09/18/2003	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A3	WO	01/77181	A2	Laboratoire Francais du Francionnement et des Biotechnologies	10/18/2001		A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A4	CARTRON et al., "Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene," Blood, February 1, 2002, vol. 99, no. 3, pp. 754-758.	
	A5	SHIELDS et al., "Lack of Fucose on Human IgG1 N-linked Oligosaccharide Improves Binding to Human FcγRIIIa and Antibody-dependent Cellular Toxicity," J. Biol. Chem., July 26, 2002, vol. 277, no. 30, pp. 26733-26740.	
	A6	SHINKAWA et al., "The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," J. Biol. Chem., January 31, 2003, vol. 278, no. 5, pp. 3466-3473.	
	A7	VIDOVIC et al., "Selective Apoptosis of neoplastic cells by the HLA-DR-specific monoclonal antibody," Cancer letters, 1998, vol. 128, pp. 127-135.	
	A8	WRIGHT et al., "Effect of glycosylation on antibody function: implications for genetic engineering," Trends in Biology, 1997, vol. 15, no. 1, pp. 26-32.	

Examiner Signature	Date Considered	
--------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.